XML 16 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
YearSummary Compensation Table Total for
John Houston, Ph.D.¹
($)
Compensation Actually Paid to
John Houston, Ph.D.¹˒²˒³
($)
Average Summary Compensation Table Total for
Non-PEO NEOs¹
($)
Average Compensation Actually Paid to
Non-PEO NEOs¹˒²˒³
($)
Value of Initial Fixed $100 Investment based on:4
Net Income
($ Millions)
Total Shareholder Return
($)
Peer Group Total Shareholder Return
($)
202412,746,9813,228,2693,420,3571,277,26046.65118.20(199)
20237,627,0325,982,9322,733,0342,167,245100.17118.87(367)
20229,545,846(6,680,330)3,521,254(1,686,145)83.26113.65(283)
202112,601,0149,298,5654,261,2853,296,740199.90126.45(191)
20208,019,78126,459,6222,892,6308,267,864206.69126.42(119)
       
Named Executive Officers, Footnote John Houston, Ph.D., was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
2020 - 20232024
Sean CassidyAndrew Saik
Ronald Peck, M.D.Sean Cassidy
Ian Taylor, Ph.D.Randy Teel, Ph.D.
Noah Berkowitz, M.D., Ph.D.
Angela Cacace, Ph.D.
Ian Taylor, Ph.D.
       
Peer Group Issuers, Footnote The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.        
PEO Total Compensation Amount $ 12,746,981 $ 7,627,032 $ 9,545,846 $ 12,601,014 $ 8,019,781
PEO Actually Paid Compensation Amount $ 3,228,269 5,982,932 6,680,330 9,298,565 26,459,622
Adjustment To PEO Compensation, Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Option Awards column are the totals from the Option Awards column set forth in the Summary Compensation Table.
YearSummary Compensation Table Total for PEO
($)
Exclusion of Equity Awards for PEO
($)
Inclusion of Equity Values for PEO
($)
Compensation Actually Paid to PEO
($)
202412,746,981(11,622,357)2,103,6453,228,269
YearAverage Summary Compensation Table Total for Non-PEO NEOs
($)
Average Exclusion of Equity Awards for Non-PEO NEOs
($)
Average Inclusion of Equity Values for Non-PEO NEOs
($)
Average Compensation Actually Paid to Non-PEO NEOs
($)
20243,420,357(2,902,813)759,7161,277,260
YearYear-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for PEO
($)
Change in Fair Value from Last Day of Prior Year to Last Day of Year of Outstanding and Unvested Equity Awards Granted in any Prior Year for PEO
($)
Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for PEO
($)
Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards Granted in any Prior Year that Vested During Year for PEO
($)
Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO
($)
Total - Inclusion of
Equity Values for PEO
($)
20244,516,879(2,532,665)119,4312,103,645
       
Non-PEO NEO Average Total Compensation Amount $ 3,420,357 2,733,034 3,521,254 4,261,285 2,892,630
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,277,260 2,167,245 1,686,145 3,296,740 8,267,864
Adjustment to Non-PEO NEO Compensation Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Option Awards column are the totals from the Option Awards column set forth in the Summary Compensation Table.
YearSummary Compensation Table Total for PEO
($)
Exclusion of Equity Awards for PEO
($)
Inclusion of Equity Values for PEO
($)
Compensation Actually Paid to PEO
($)
202412,746,981(11,622,357)2,103,6453,228,269
YearAverage Summary Compensation Table Total for Non-PEO NEOs
($)
Average Exclusion of Equity Awards for Non-PEO NEOs
($)
Average Inclusion of Equity Values for Non-PEO NEOs
($)
Average Compensation Actually Paid to Non-PEO NEOs
($)
20243,420,357(2,902,813)759,7161,277,260
YearAverage Year-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Non-PEO NEOs
($)
Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Outstanding and Unvested Equity Awards Granted in any Prior Year for Non-PEO NEOs
($)
Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs
 ($)
Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards Granted in any Prior Year that Vested During Year for Non-PEO NEOs
($)
Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs
($)
Total - Average Inclusion of Equity Values for Non-PEO NEOs
 ($)
20241,444,680(323,542)54,381(415,803)759,716
       
Compensation Actually Paid vs. Total Shareholder Return
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the four most recently completed fiscal years and the Nasdaq Biotechnology Index TSR over the same period.
Comp Paid vs TSR.jpg
       
Compensation Actually Paid vs. Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average Compensation Actually Paid to our Non-PEO NEOs, and our net income during the four most recently completed fiscal years.
Comp Paid vs Net Income.jpg
       
Total Shareholder Return Vs Peer Group
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the four most recently completed fiscal years and the Nasdaq Biotechnology Index TSR over the same period.
Comp Paid vs TSR.jpg
       
Total Shareholder Return Amount $ 46.65 100.17 83.26 199.90 206.69
Peer Group Total Shareholder Return Amount 118.20 118.87 113.65 126.45 126.42
Net Income (Loss) $ (199,000,000) $ (367,000,000) $ (283,000,000) $ (191,000,000) $ (119,000,000)
PEO Name John Houston, Ph.D.,        
Additional 402(v) Disclosure The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by our named executive officers during the applicable years. These amounts reflect the Summary Compensation Table Total with certain adjustments made in accordance with Item 402(v) and as described in footnote 3 below.        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (11,622,357)        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,103,645        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 4,516,879        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,532,665)        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 119,431        
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,902,813)        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 759,716        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,444,680        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (323,542)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 54,381        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (415,803)